Every year, millions of people are diagnosed with cancer, and cancer has now become a serious disease, and it appears to have been carried out on 714 patients. 363 people were given pembrolizumab in the test, and 351 people were treated only with conventional treatment—radiotherapy after surgery to remove the tumor, and the conventional treatment of head and neck cancer has not changed in the last 20 years. Most of these patients do not survive for five years.
A researcher recently claimed to have discovered the effective drug twice the current treatment of head and neck cancer, which was recently presented at the annual conference of the American Society of Clinical Oncology, which is seen as the most revolutionary success of two decades in medical science, according to the British daily Guardian.
The discovered immunotherapy drug pembrolizumab activates the body's immune system, which works by targeting a specific protein in the patient's body, which Helps to destroy cancer cells.
The newly discovered drug has been controlled by the newly discovered drug for 5 years in some patients, but if given with the conventional treatment, it remains effective for 30 months. The test was conducted by 700 patients from 192 areas of 24 countries, and the research team conducted the study by the research team of the Washington University School of Medicine in the United States, which was conducted by the research team, including Professor of Oncology. ‘This is the first time such an effect has been seen in a drug, a very important and amazing achievement," Douglas Adkins said.
The oncology department of medical science, which is known as an oncologist, has already started using the drug as a modern antidote to the head and neck cancer.
This immunotherapy has worked better, especially if the immune marker of PD-L1 is high, but it has stopped the disease completely in the case of all types of throat and mouth cancer patients.
Kevin Harrington, a professor of biological cancer therapy at the Institute of Cancer Research in London, led the UK-based research team, which was funded by pharmaceutical manufacturer MSD.
He said that this immunotherapy is very effective for patients who have spread or returned cancer, but this is the first time that new patients have proven effectiveness.
‘When cancer cells start to spread, the treatment becomes extremely difficult, but immunotherapy significantly reduces the risk of cancer cells spreading significantly, this study has shown.
The test showed that pembrolizumab kept patients in a disease-free condition longer than conventional treatments. It is the best job for patients with high immune markers in their body, but the hope is that whatever the level of immune marker is, this drug has improved the results of treatment in all patients with head and throat cancer.
